CodeSystem-nkrs-typerecurrencetransformation

Sourcech.fhir.ig.ch-crl#0.9.0:CH CRL (R4) (v4.0.1)
resourceTypeCodeSystem
idnkrs-typerecurrencetransformation
canonicalhttp://fhir.ch/ig/ch-crl/CodeSystem/nkrs-typerecurrencetransformation
version0.9.0
statusactive
publisherBundesamt für Gesundheit BAG
nameNkrsTypeRecurrenceTransformation
titleNKRS - Type of Recurrence/Transformation
date2022-02-04T14:14:21+01:00
descriptionThe data item records the type of first recurrence of the disease or the occurrence of a transformation. **Type of recurrence(s)/transformation(s) (Variable number: 8.1)** in \'NATIONAL CANCER DATA DICTIONARY, V 1.1, Part A, BASIC VARIABLES for Adults, Adolescents, and Children (23.12.2019)\' ([EN](https://www.nacr.ch/assets/files/uploads/a-datadictionary-basicvariables-v1.1.pdf), [DE](https://www.nkrs.ch/assets/files/uploads/a-datenstruktur-variablen-der-basisdaten-v1.1.pdf), [FR](https://www.onec.ch/assets/files/uploads/a-dict-des-donnees-variables-de-base-v1.1.pdf), [IT](https://www.snrt.ch/assets/files/uploads/a-dati-oncologici-variabili-di-base-v1.1.pdf))
copyrightCC-BY-SA-4.0
jurisdictionsch
caseSensitivetrue
valueSethttp://fhir.ch/ig/ch-crl/ValueSet/nkrs-typerecurrencetransformation
contentcomplete
Usages

This case-sensitive code system http://fhir.ch/ig/ch-crl/CodeSystem/nkrs-typerecurrencetransformation defines the following codes:

Code Display Definition
1 Progression Locoregional new findings without disease free intermission. For example: the tumour that is still present starts to progress after a period of stabilisation.
2 Transformation The development of one ICD-O M term into another (for example, the change of a haematopoetic or lymphoid neoplasm from chronic to acute phase). In order to decide on haematological transformation event, adherence to the ENCR recommendation and Haemacare guideline, cited below, is mandatory.
3 Metastasis New finding at a site distant to the primary tumour, i.e. metachronous metastasis. Either with or without disease free intermission.
4 Relapse Locoregional new findings after a period of documented disease-free intermission or remission without detectable tumour.

Produced 08 Sep 2023